Tenaya Therapeutics

Faraz Ali, CEO
San Francisco, CA
Tenaya Therapeutics is a biopharmaceutical company with a mission to discover, develop, and deliver potentially curative treatments that target the underlying causes of heart disease. Tenaya is advancing first-in-class product candidates from three separate platforms – cellular regeneration, gene therapy, and precision medicine. The cellular regeneration platform uses AAV vectors to deliver proprietary transcription factors that drive in vivo reprogramming of resident cardiac fibroblasts into cardiomyocytes, with an initial focus on heart failure post-myocardial infarction. The gene therapy platform uses AAV vectors for the targeted delivery and expression of therapeutic payloads to specific cells in the heart, with an initial focus on the treatment of genetically-defined cardiomyopathies. The precision medicine platform uses isogenic iPSC-derived cardiomyocytes as human disease models to identify new heart failure targets and to screen for therapeutic compounds in a modality agnostic manner, with an initial focus on small molecules for the treatment of genetically-defined dilated cardiomyopathies.

By using this website you agree to accept our Privacy Policy and Terms & Conditions